PF 4629991
Alternative Names: PF-4629991Latest Information Update: 28 Jan 2010
At a glance
- Originator Pfizer
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 27 Jan 2010 Discontinued - Phase-I for Rheumatoid arthritis in USA (unspecified route)
- 31 Mar 2009 Phase-I clinical trials in Rheumatoid arthritis in USA (unspecified route)